Survodutide: the glucagon/GLP-1 dual agonist in trials, explained

Prepared by: Research Desk. Sources are linked for verification.

Survodutide is an investigational injectable peptide that activates two hormone receptors at once: the glucagon receptor and the GLP-1 receptor. It is being studied in two overlapping areas. One is obesity, including obesity with type 2 diabetes. The other is metabolic dysfunction-associated steatohepatitis (MASH), a progressive form of fatty liver disease. This explainer covers what the molecule is designed to do and what the published trials measured. It also sets out the molecule's regulatory position and how its data can be read alongside other pipeline programs.

Status label: Investigational. Survodutide is not approved by the FDA for any use. For how it fits among other programs, see our master tracker, The GLP-1 pipeline in 2026.

Survodutide at a glance

Why combine glucagon and GLP-1?

Most of the obesity medicines now on the market are built around the GLP-1 receptor. A 2024 review in Diabetes Care summarised the evidence on GLP-1 medicines in type 2 diabetes and obesity. It covered their effects on glucose control and body weight, and the gastrointestinal adverse events that are common across the class [5].

Glucagon is better known for raising blood glucose, so pairing it with a GLP-1 agonist can seem odd at first. The research rationale is that glucagon receptor activity acts on the liver and on energy use in ways GLP-1 agonism alone does not. Meanwhile, the GLP-1 component is expected to offset glucagon's glucose-raising effect. A 2025 systematic review of emerging obesity pharmacotherapies in Pharmacological Reviews placed glucagon-containing co-agonists among the main new mechanistic classes under study [6]. Survodutide is one of them.

The liver angle explains why survodutide has its own MASH program. Most GLP-1 drugs were developed for diabetes or weight first, with liver outcomes studied later. For survodutide, liver fat and fibrosis were a primary research question from an early stage.

The phase 2 MASH trial (human, randomized)

The most detailed published survodutide data in liver disease come from a phase 2 randomized, placebo-controlled trial published in the New England Journal of Medicine in 2024 [1].

What was studied. Adults with biopsy-confirmed MASH and liver fibrosis were randomly assigned to one of three survodutide levels or to placebo. They were followed for 48 weeks.

What was measured. The primary endpoint was histological: improvement in MASH with no worsening of fibrosis, judged on liver biopsy. Secondary endpoints included changes in fibrosis stage and in liver fat content.

What was reported. A larger share of participants in each survodutide group met the primary histological endpoint than in the placebo group. Gastrointestinal adverse events, mainly nausea, diarrhoea and vomiting, were reported more often with survodutide than with placebo [1].

How to read it. This was a phase 2 trial, designed to choose levels and estimate effect sizes for later trials. It was not designed to establish long-term outcomes. Biopsy-based endpoints are the standard in MASH research, but liver biopsy is subject to sampling variation, and phase 2 results are often smaller in later phase 3 testing.

Survodutide among other MASH candidates

A 2025 systematic review and network meta-analysis in Hepatology compared pharmacological agents studied in MASH. It looked at two outcomes: fibrosis regression and MASH resolution [7]. Network meta-analyses rank agents that were never tested head to head, using a shared comparator such as placebo. Rankings of this kind depend on trial length, how sick the enrolled populations were and how biopsies were read. They are best read as hypothesis-generating, not as a final league table.

Obesity with type 2 diabetes (human, randomized)

Survodutide's obesity program has moved into larger trials. In 2026 the New England Journal of Medicine published a trial of survodutide in adults with obesity and type 2 diabetes [2]. Readers comparing this population with others should keep one pattern in mind. Across GLP-1-based drugs, people with type 2 diabetes tend to show smaller weight reductions than people without diabetes in otherwise similar trials [5]. Our pillar page covers this point with side-by-side examples.

For exact figures, endpoint definitions and adverse-event tables, the original publication [2] is the reference. Two details matter most when comparing these numbers with other drugs:

1. Which estimand is quoted. A treatment-regimen estimand counts everyone randomized, whether or not they kept receiving the study drug. An efficacy estimand assumes continued exposure. The second figure is usually larger.

2. How long the trial ran. Weight curves with incretin-based drugs often continue to move for many months. A shorter trial can understate where a curve eventually settles.

How survodutide compares with related molecules

Mazdutide shares survodutide's dual target, but its published program has centred on Chinese populations [3]. A separate page on mazdutide is planned. Retatrutide adds GIP receptor activity to the glucagon and GLP-1 pair, making it a triple agonist [4]. Comparisons across these molecules are indirect. The trials differ in population, duration, estimand and background care, so any cross-trial ranking should be read with caution.

Safety signals reported so far

Across the published survodutide trials, the most frequently reported adverse events were gastrointestinal [1]. This pattern is consistent with the broader GLP-1 class [5]. Because survodutide also acts on the glucagon receptor, researchers watch for effects linked to that pathway, such as changes in heart rate and glucose. These are among the questions larger and longer trials are designed to answer. No phase 2 trial can fully characterise rare adverse events. That is one reason regulators expect large phase 3 datasets before any approval decision.

Regulatory status and the unapproved market

Survodutide is investigational. Outside a registered clinical trial, there is no FDA-approved survodutide product. The FDA has warned that unapproved GLP-1-type products sold online, including those labelled "for research use only", have not been reviewed for safety, effectiveness or quality [8]. Our regulatory explainer, Compounded, counterfeit and "research" GLP-1s: what the FDA says, sets out the agency's position on each category in detail.

This site reports published research and regulatory records only. It does not describe how any investigational compound is obtained or used. Our sourcing and disclosure standards are described on the About page.

Frequently asked questions

Is survodutide approved anywhere by the FDA?

No. As of the date on this page, survodutide is an investigational drug that has not been approved by the FDA for any use. Its data come from randomized clinical trials, including a phase 2 MASH trial [1] and a 2026 trial in obesity with type 2 diabetes [2].

How is survodutide different from GLP-1-only drugs?

GLP-1-only drugs act on a single receptor [5]. Survodutide also activates the glucagon receptor, a pathway studied for its effects on the liver and on energy use [6]. That second target is the main reason survodutide has a dedicated liver-disease research program.

Why do survodutide results differ between trials?

The trials enrolled different populations: people with MASH and fibrosis [1], and people with obesity and type 2 diabetes [2]. They also measured different primary endpoints, such as biopsy-based liver outcomes versus body-weight change. Trial length and the estimand reported also change the headline figures.

Further reading: choosing a book on drug development and obesity science

Trial papers report numbers. Books can explain how those numbers come about: how a molecule moves from discovery to phase 3, why endpoints are chosen, and how regulators weigh risk. Readers comparing books in this area can use a few neutral criteria:

• Evidence quality: endnotes or references to peer-reviewed studies, not just anecdotes.

• Recency: the publication date matters in a field that changes year to year. Check whether the edition covers developments from the past two or three years.

• Scope: some titles focus on the business of drug development, others on appetite and metabolism biology. Choose the one that matches the question being researched.

• Author background: look for authors with research, regulatory or science-journalism experience, and for clear separation of evidence from opinion.

• Format and price: print, e-book and audio editions often differ in price. Library availability is worth checking before purchase.

Reading lists are revisited when notable new titles appear. Selection uses the same neutral criteria listed above.

Last updated: 19 October 2026.

Related on this site

• Weight Peptide Labs home

• Compounded, counterfeit and 'research' GLP-1s: what the FDA says

• The GLP-1 pipeline in 2026: every major weight-loss drug, tracked

• Books on obesity science and the drug race: a 2026 reading list

• How to read obesity drug trials: a 10-point checklist

• Fitness tracker accuracy: how to compare wearables and their data

Not medical advice. This page reports published research and regulatory records for information only.

Research-only notice: Content on this site is provided for research and educational purposes only and is not intended for human use. It is not medical advice.

Translation notice: Some content on this site may have been machine-translated using Google Translate and may contain errors.